Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: apoptosis modulating compounds - Theraptosis

Drug Profile

Research programme: apoptosis modulating compounds - Theraptosis

Alternative Names: TRP 1; TRP 101; TRP 2; TRP 302; TRP 5; TRP 601; TRP 602; TRP 603; TRP 701; TRPXX

Latest Information Update: 06 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Theraptosis
  • Class
  • Mechanism of Action Apoptosis inhibitors; Apoptosis stimulants; Caspase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic brain damage
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Chronic brain damage; Neurological disorders; Stroke

Most Recent Events

  • 21 Oct 2009 Pharmacodynamics data from preclinical trials in neonatal brain damage presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
  • 06 Dec 2006 Preclinical trials in Cancer in France (unspecified route)
  • 06 Dec 2006 Preclinical trials in Neurological disorders in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top